LC
PCVX icon

Lindbrook Capital’s Vaxcyte PCVX Stock Holding History

Lindbrook Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$21.4K Sell
568
-46
-7% -$3.68K ﹤0.01% 1320
2024
Q4 		$50.3K Sell
614
-2
-0.3% -$199 ﹤0.01% 809
2024
Q3 		$70.4K Sell
616
-122
-17% -$11K 0.01% 682
2024
Q2 		$55.7K Buy
738
+325
+79% +$22.1K 0.01% 746
2024
Q1 		$28.2K Buy
413
+2
+0.5% +$138 ﹤0.01% 1040
2023
Q4 		$25.8K Sell
411
-4
-1% -$208 ﹤0.01% 1045
2023
Q3 		$21.2K Buy
415
+7
+2% +$345 ﹤0.01% 1033
2023
Q2 		$20.4K Buy
408
+81
+25% +$3.84K ﹤0.01% 1081
2023
Q1 		$12.3K Buy
327
+186
+132% +$7.89K ﹤0.01% 1319
2022
Q4 		$6.76K Buy
141
+103
+271% +$4.04K ﹤0.01% 1644
2022
Q3 		$1K Buy
38
+27
+245% +$684 ﹤0.01% 2447
2022
Q2 		$0 Sell
11
-58
-84% -$1.34K ﹤0.01% 2695
2022
Q1 		$2K Buy
+69
New +$1.51K ﹤0.01% 2049
2021
Q3 		– Sell
-17
Closed – – 1967
2021
Q2 		$0 Buy
+17
New +$348 ﹤0.01% 1981

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Lindbrook Capital's PCVX Position: Q1 2025 in Review

Lindbrook Capital reduced its Vaxcyte (PCVX) stake by 7.5% in Q1 2025, selling an estimated $3.68K and leaving 568 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1320.

Lindbrook Capital first reported a position in PCVX in Q2 2021 and has held it in 14 quarters since. The position peaked at $70.4K in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Lindbrook Capital held 568 shares of Vaxcyte worth $21.4K as of Q1 2025.
  • Lindbrook Capital sold 46 Vaxcyte shares in Q1 2025, an estimated $3.68K.
  • Vaxcyte made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1320 holding.
  • Lindbrook Capital first reported a position in Vaxcyte in Q2 2021 and has held it in 14 quarters since.
  • Lindbrook Capital's Vaxcyte position peaked at $70.4K in Q3 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.